SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 94 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 0.69 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,202,961 | -20.1% | 157,120 | +1.9% | 0.00% | 0.0% |
Q1 2024 | $5,257,612 | +17.4% | 154,137 | -0.4% | 0.00% | 0.0% |
Q4 2023 | $4,478,553 | +7.6% | 154,753 | +2.5% | 0.00% | 0.0% |
Q3 2023 | $4,163,842 | -10.2% | 151,028 | -2.1% | 0.00% | -50.0% |
Q2 2023 | $4,636,815 | -18.0% | 154,252 | -1.2% | 0.00% | 0.0% |
Q1 2023 | $5,656,590 | -19.2% | 156,130 | -20.5% | 0.00% | -33.3% |
Q4 2022 | $7,003,128 | +12.8% | 196,331 | +7.1% | 0.00% | +50.0% |
Q3 2022 | $6,207,000 | +40.5% | 183,367 | +20.0% | 0.00% | 0.0% |
Q2 2022 | $4,418,000 | -7.8% | 152,767 | +3.0% | 0.00% | +100.0% |
Q1 2022 | $4,794,000 | -14.7% | 148,312 | -23.1% | 0.00% | -50.0% |
Q4 2021 | $5,622,000 | +11.4% | 192,787 | +1.9% | 0.00% | 0.0% |
Q3 2021 | $5,046,000 | +22.6% | 189,202 | +41.6% | 0.00% | +100.0% |
Q2 2021 | $4,115,000 | -6.9% | 133,651 | -20.9% | 0.00% | -50.0% |
Q1 2021 | $4,421,000 | +5.1% | 168,885 | +1.0% | 0.00% | 0.0% |
Q4 2020 | $4,207,000 | +21.0% | 167,215 | +0.2% | 0.00% | 0.0% |
Q3 2020 | $3,478,000 | -11.8% | 166,902 | +0.5% | 0.00% | 0.0% |
Q2 2020 | $3,944,000 | +40.3% | 166,044 | +6.2% | 0.00% | 0.0% |
Q1 2020 | $2,812,000 | -23.6% | 156,315 | +0.7% | 0.00% | 0.0% |
Q4 2019 | $3,680,000 | -2.7% | 155,155 | +12.7% | 0.00% | 0.0% |
Q3 2019 | $3,782,000 | -14.7% | 137,620 | +2.7% | 0.00% | 0.0% |
Q2 2019 | $4,433,000 | -5.7% | 133,961 | -0.2% | 0.00% | -33.3% |
Q1 2019 | $4,702,000 | +16.6% | 134,189 | +9.6% | 0.00% | 0.0% |
Q4 2018 | $4,033,000 | -33.2% | 122,407 | +1.8% | 0.00% | -25.0% |
Q3 2018 | $6,039,000 | -8.2% | 120,214 | +8.4% | 0.00% | -20.0% |
Q2 2018 | $6,582,000 | +37.4% | 110,896 | +6.0% | 0.01% | +25.0% |
Q1 2018 | $4,791,000 | +18.4% | 104,580 | +3.1% | 0.00% | +33.3% |
Q4 2017 | $4,046,000 | +3.5% | 101,460 | +3.8% | 0.00% | 0.0% |
Q3 2017 | $3,910,000 | +0.7% | 97,778 | +8.5% | 0.00% | 0.0% |
Q2 2017 | $3,881,000 | +50.7% | 90,087 | +9.5% | 0.00% | +50.0% |
Q1 2017 | $2,575,000 | +25.5% | 82,272 | +1.2% | 0.00% | 0.0% |
Q4 2016 | $2,052,000 | +101.2% | 81,278 | +97.0% | 0.00% | +100.0% |
Q3 2016 | $1,020,000 | +613.3% | 41,249 | +466.5% | 0.00% | – |
Q2 2016 | $143,000 | +72.3% | 7,282 | +35.9% | 0.00% | – |
Q1 2016 | $83,000 | +5.1% | 5,358 | -7.9% | 0.00% | – |
Q4 2015 | $79,000 | 0.0% | 5,818 | 0.0% | 0.00% | – |
Q3 2015 | $79,000 | -17.7% | 5,818 | 0.0% | 0.00% | – |
Q2 2015 | $96,000 | +43.3% | 5,818 | 0.0% | 0.00% | – |
Q1 2015 | $67,000 | +36.7% | 5,818 | 0.0% | 0.00% | – |
Q4 2014 | $49,000 | -3.9% | 5,818 | 0.0% | 0.00% | – |
Q3 2014 | $51,000 | – | 5,818 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |